- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02351297
Effects of High Protein Diet on the Large Intestine in Overweight Humans
Study Overview
Status
Conditions
Detailed Description
High protein diets are widely used for their slimming effect. Those diets increase the quantity of undigested protein and peptides reaching the large intestine. Microbiota utilizes protein and peptides as substrates and produces amino-acid derived metabolites such as short chain fatty acids, branched chain fatty acids, lactate, formate, succinate, ammonium, hydrogen sulfide and phenolic compounds. Some of those metabolites have been shown to be beneficial to the host whereas other could be deleterious. High protein diets may have different effects whether based on animal or plant proteins since those two kinds of protein have different amino acids composition and slightly different digestibility. The objective of this study is to evaluate in overweight volunteers the consequences of high protein diets (animal vs vegetal) vs isocaloric-normoproteic diet at the level of the large intestine and metabolism. Firstly, composition and activity of the microbiota and the metabolites produced in the large intestine lumen will be determined. Then, to evaluate the consequences of the tested diets on mucosal physiology, gene expression will be analyzed in rectal biopsies and fecal water will be tested on colonocytes cell lines. Lastly, the consequences of the diets on host metabolism will be evaluated.
Dietary intervention
Before the study, volunteers (n=42) will provide a 3 day food record that will be utilized by a dietician to calculate their usual energy intake. The study will start with a 2 weeks normalization period during which the volunteers will have to eat according to menus (Fig. 1). The diet will provide to the volunteer their usual individual energy intake; and protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake.
At the end of this standardization period, volunteers will be randomly assigned into 3 groups (n=14) for 3 weeks (intervention period) (Fig. 1). Volunteers of the 3 groups will follow a diet with a reduced digestible carbohydrates intake (15% of energy intake) while undigestible carbohydrate intake will remain unchanged. The volunteers will consume 3 times per day a dietary supplement powder that they will dissolve in water and then drink. This supplement will provide them 15% of their energy intake. The first group will receive a casein (animal protein) supplement so that they will have a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The second group will receive a soy protein(vegetal) supplement so that they will also consume a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The third group will receive a maltodextrin (digestible carbohydrate, placebo control) supplement so that they will ingest a normoproteic diet, similar in macronutrient composition to the standardization diet (protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake). The dietary supplement will be given in a double-blinded protocol. There will be no energy restriction between the standaridization and intervention periods.
Clinical protocol
Daily, the volunteers will measure their body weight and record their food consumption and physical activity. Once a week, they will have a phone call with a dietician to ensure dietary compliance (Fig. 2).
At the end of the normalization period, 13 days after the beginning of the study (D13), volunteers will collect 24h urine samples. Stool samples will be collected from the evening of D13 to the morning of D14 . A cooler will be provided to the volunteer for storage and transport of samples. After one night fasting, in the morning of D14, the volunteers will come to the hospital and will bring their samples that will be immediately conditioned for storage. Blood samples will be collected. Then, rectal biopsies will be recovered. Every week during the intervention period, urine stool and blood will be sampled (D21, D28, D35). At the end of the intervention period, rectal biopsies will be recovered (D35). Body weight and blood pressure will be measured at each visit.
Analyses All measured parameters will be expressed relatively to baseline.
Dietary intake will be evaluated by dietician based on food records.
Stool samples
- Microbiota composition and functions
- Luminal metabolites composition
- pH, osmolarity, water content
- Fecal water test on HT-29 cells (colonocytes) for mitochondrial respiration, proliferation, genotoxicity, cytotoxicity, gene expression
Urines
- Urea and creatinine assay (protein consumption marker to verify dietary compliance)
- Metabolomics
Blood
- Clinical parameters (total cholesterol, LDL and HDL cholesterol, non-esterified fatty acids, triglycerides, glycemia, insulinemia)
- Metabolomics
Rectal biopsies
• Transcriptomic analyses
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 25- 30
- Body weight stable last 3 months
- Moderate physical activity
Exclusion Criteria:
- Abnormal food behavior
- Digestive, renal, hepatic, pulmonary, hemostasis, neoplasic diseases
- antibiotic, pre or probiotics use in the last 3 months
- intolerance for the tested product
- positive serology for infectious disease
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Casein supplementation
After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
|
After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
|
Experimental: Soy protein supplementation
After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
|
After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
|
Placebo Comparator: Maltrodextrin supplementation
After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
|
After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gene expression in rectal biopsy from baseline after 3 week dietary intervention
Time Frame: Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention
|
Gene expression in biopsies collected before (baseline) and after 3 week dietary intervention will be measured by transcriptomic analyses.
Differential gene expression will be expressed as relative units (fold change).
|
Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
microbiota composition analysis
Time Frame: Change for baseline in microbiota composition after 3 weeks dietary intervention
|
Microbiota composition will be analysed in stool samples before (baseline) and after 3 week dietary intervention using metagenomic analyses and will be expressed as bacterial relative abundance.
|
Change for baseline in microbiota composition after 3 weeks dietary intervention
|
fecal water metabolomics
Time Frame: Change for baseline in fecal water metabolites after 3 weeks dietary intervention
|
Fecal water metabolites will be analysed in stool samples before (baseline) and after 3 week dietary intervention using RMN analyses and will be expressed as metabolites relative abundance.
|
Change for baseline in fecal water metabolites after 3 weeks dietary intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert BENAMOUZIG, MD PhD, Avicenne Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-A01730-45
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on casein supplementation
-
Maastricht University Medical CenterCompletedObesity | Overweight | Satiety | Overeating | Ileal BrakeNetherlands
-
Texas A&M UniversityCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Texas A&M UniversityUnknown
-
NIZO Food ResearchFrieslandCampinaCompleted
-
Université de SherbrookeUnknownSystolic Heart Failure | Sub-clinical HypothyroidismCanada
-
Maastricht University Medical CenterBioActor B.V.Recruiting
-
University of Missouri-ColumbiaAlmond Board of CaliforniaRecruiting
-
Charite University, Berlin, GermanyFreie Universität Berlin, Institute of Biology/Genetic, Berlin,Germany; Karl-Franzens-Universität...CompletedSubjective Cognitive DeclineGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedEsophagitis | Mucositis | Malignant NeoplasmUnited States
-
University of Alabama at BirminghamChildren's Health System, AlabamaActive, not recruitingPremature InfantUnited States